

September 07, 2023

The Manager, Listing Department
The National Stock Exchange of India Ltd.
Exchange Plaza, Bandra Kurla Complex,
Bandra (E), Mumbai - 400 051
NSE Symbol: PANACEABIO

BSE Limited Corporate Relationship Department, Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai - 400 001 BSE Scrip Code: 531349

Sub: Business Responsibility and Sustainability Report for the Financial Year 2022-23

Dear Sir/Madam,

Pursuant to the provisions of Regulation 34(2)(f) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed herewith the Business Responsibility and Sustainability Report ("BRSR") for the Financial Year 2022-23.

The BRSR forming part of the Annual Report for the financial year 2022-23 can also be accessed on the website of the Company at the link, https://www.panaceabiotec.com/en/section/information-repository/annual-report.

This is for your kind information and record please.

Thanking you,

Sincerely yours,

for Panacea Biotec Limited

Vinod Goel Group CFO and Head Legal & Company Secretary

Encl.: As Above

This Business Responsibility & Sustainability Report ("BRSR") for the financial year ended March 31, 2023 conforms to the Business Responsibility & Sustainability Reporting requirement pursuant to Regulation 34(2)(f) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI LODR Regulations"), which has mandated the inclusion of BRSR as part of the Company's Annual Report for top 1000 listed entities based on market capitalisation (calculated as on March 31 of every financial year) and the National Voluntary Guidelines (NVGs) on Social, Environmental and Economic Responsibilities of Business issued by Ministry of Corporate Affairs, Government of India.

The Company has not instituted any process to monitor / verify whether any other entity / entities (e.g. suppliers, distributors etc.) that the Company does business with, participate in the Business Responsibility initiatives of the Company.

SECTION A: GENERAL DISCLOSURES

ı.	Details of the listed entity	
1.	Corporate Identity Number (CIN) of the Listed Entity	L33117PB1984PLC022350
2.	Name of the Listed Entity	Panacea Biotec Limited
3.	Year of incorporation	1984
4.	Registered office address	Ambala-Chandigarh Highway, Lalru, Punjab – 140501, India
5.	Corporate address	B-1 Extn. / G-3 Mohan Co-operative Industrial Estate, Mathura Road, New Delhi - 110044
6.	E-mail	companysec@panaceabiotec.com
7.	Telephone	+91-11-41679000, 41578000
8.	Website	www.panaceabiotec.com
9.	Financial year for which reporting is being done	Start Date End Date
	Current Financial Year	01.04.2022 31.03.2023
	Previous Financial Year	01.04.2021 31.03.2022
	Prior to Previous Financial Year	01.04.2020 31.03.2021
10.	Name of the Stock Exchange(s) where shares are listed	a. National Stock Exchange of India Ltd. (NSE)b. BSE Ltd. (BSE)
11.	Paid-up Capital	₹22,26,20,746
12.	Name and contact details (telephone, email address) of the p	person who may be contacted in case of any queries on the BRSR
	Name	Mr. Vinod Goel, Company Secretary
	Contact	+91-11-41679015
	E-mail	vinodgoel@panaceabiotec.com
13.	Reporting boundary - Are the disclosures under this report made on a standalone basis (i.e. only for the entity) or on a consolidated basis (i.e. for the entity and all the entities which form a part of its consolidated financial statements, taken together).	Standalone basis

II. Products / Services

S. No	o. Description of main activity	Description of business activity	% of turnover of the entity	
(i)	Pharmaceuticals	Manufacturing of pharmaceuticals, medicinal, chemical and botanical products	100%	
Prod	ucts / Services sold by the entity (account	ing for 90% of the entity's Turnover):		
S. No	o. Product / Service	NIC Code	% of total turnover contributed	
(i)	Manufacturing of pharmaceuti medicinal, chemical and botar		100%	



III. Operations

1.	Number of locations where plants and/or operations / offices of the entity are situated:							
	Location	Number of plants	Number of offices	Total				
	National	3*	2	5				
	International	0	2	2				

^{*}The plants include manufacturing locations and R&D Centers.

Markets served by the entity

a. Number of locations:

LocationsNumberNational (No. of States)Pan-IndiaInternational (No. of Countries)Over 30 countries in Africa, Asia and Latin America

b. What is the contribution of exports as a percentage of the total turnover of the entity? In the reporting year, the exports contributed ~82% of total turnover of the Company.

A brief on types of Customers

The Company is one of the largest suppliers of vaccines to multilateral agencies like UNICEF, PAHO, etc. and is supplying vaccines to institutional customers and national Governments. The Company also sells its products to customers in private markets through stockiest, retailers and medical professionals.

IV. Employees

Details as at the end of Financial Year

a. Employees and workers (including differently abled):

S.No	o. Particulars	Total (A)		Male		nale
			No. (B)	% (B / A)	No.(C)	% (C / A)
Emp	oloyees					
1.	Permanent (D)	636	555	87%	81	13%
2.	Other than Permanent (E)	-	-	-	-	-
3.	Total employees (D + E)	636	555	87%	81	13%
Woı	rkers					
4.	Permanent (F)	457	457	100%	-	-
5.	Other than Permanent (G)	202	197	98%	5	2%
6.	Total workers (F + G)	659	654	99%	5	1%

b. Differently abled Employees and Workers:

S.No.	Particulars	Total (A)	M	ale	Female	
			No. (B)	% (B / A)	No.(C)	% (C / A)
Diffe	rently abled Employees					
1.	Permanent (D)	1	1	100%	-	-
2.	Other than Permanent (E)	<u> </u>	-	-	-	-
3.	Total differently abled employees (D + E)	1	1	100%	-	-
Diffe	rently abled Workers					
4.	Permanent (F)	2	2	100%	-	-
5.	Other than permanent (G)		-	-	-	-
6.	Total differently abled workers (F + G)	2	2	100%	-	-

2. Participation / Inclusion / Representation of women:

			Total (A)	No. and perce	ntage of Females
				No. (B)	% (B / A)
Board of Directors*			10	1	10%
Key Management Personnel*			5	-	-

^{*} Dr. Rajesh Jain, Chairman and Managing Director, Mr. Sandeep Jain, Joint Managing Director and Mr. Ankesh Jain, Whole-time Director designated as Director Sales & Marketing are members of the Board of Directors and also considered as Key Managerial Personnel.

3. Turnover rate for permanent employees and workers (Disclose trends for the past 3 years)

		FY 2022-23			FY 2021-22			FY 2020-21	
	Male	Female	Total	Male	Female	Total	Male	Female	Total
Permanent Employees	39%	40%	39%	32%	38%	32%	36%	24%	34%
Permanent Workers	30%		30%	43%	-	43%	14%	-	14%

V. Holding, Subsidiary and Associate Companies (including Joint Ventures)

(a)	Nam	Names of holding / subsidiary / associate companies / joint ventures									
	S.No	o. Name of the holding / subsidiaries / associate companies / joint ventures (A)	Indicate whether holding / subsidiary / associate / joint venture	% of shares held by listed entity	Does the entity indicated at column A, participate in the Business Responsibility initiatives of the listed entity? (Yes/No)						
	1	Panacea Biotec Pharma Limited	Subsidiary	100%	No						
	2	Meyten Realtech Private Limited	Subsidiary	100%	No						
	3	Panacea Biotec (International) SA	Subsidiary	100%	No						
	4	Panacea Biotec Germany GmbH	Subsidiary	100%	No						
	5	PanEra Biotec Private Limited	Associate	50%	No						
	6	Adveta Power Private Limited	Joint Venture	50%	No						

VI. CSR Details

1.	(i)	Whether CSR is applicable as per section 135 of Companies Act, 2013? (Yes/No)	No
	(ii)	Turnover (in ₹)	NA
	(iii)	Net worth (in ₹)	NA

VII. Transparency and Disclosures Compliances

Stakeholder group from whom	Grievance	(If Yes, then		FY 2022-23			FY 2021-22	
complaint is received	Redressal Mechanism in Place (Yes/ No)	provide web-link for policy)*	Number of complaints filed during the year	Number of complaints pending resolution at close of the year	Remarks	Number of complaints filed during the year	Number of complaints pending resolution at close of the year	Remarks
Communities	Yes	*	-	-	-	-	-	-
Investors other than shareholders	NA	NA	NA	NA	NA	NA	NA	NA
Shareholders	Yes	*	-	-	-	1		
Employees and workers	Yes	*	-	-	-	"	-	
Customers	Yes	*	7	-	- ,	6	· -	-
Value Chain Partners	Yes	*	-	_	· -			· <u>:</u> ·

^{*} The policies relating to grievance redressal mechanism are available at Company's website at https://www.panaceabiotec.com. In addition, there are internal policies placed on the intranet of the Company.

2. Overview of the entity's material responsible business conduct issues:

Indicate Material responsible business conduct and sustainability issues pertaining to environmental and social matters that present a risk or an opportunity to your business, rationale for identifying the same, approach to adapt or mitigate the risk along with its financial implications:

S. No.	Material issue identified	Whether risk or opportunity (R/O)	Rationale for identifying the risk / opportunity	In case of risk, approach to adapt or mitigate	Financial implications of the risk or opportunity (Indicate positive or negative implications)
1	Product Quality, Safety and availability	Risk	It is critical to address risks relating to product quality and safety issues. Non-availability of products may lead to loss of business	standards, procedures and policy of the Company. Compliance with cGMP, GLP practices, Pharmacovigilance processes and SOPs. Adoption of technological interventions, training on cGMP standards, automation and	sustainable business and relations with stakeholders. Availability of products across the markets helps in increasing market share and customer satisfaction. Negative: These issues, if not addressed on time, can have serious impact on the business operations, lead to penalties and
2	Business Ethics and Corporate Governance	Risk	External regulatory environment on corporate ethics and corporate	principles within the Company to	governance practices and ethical



S. No.	Material issue identified	Whether risk or opportunity (R/O)	Rationale for identifying the risk / opportunity	In case of risk, approach to adapt or mitigate	Financial implications of the risk or opportunity (Indicate positive or negative implications)
			governance is dynamic in nature. Ethical business standards, and framework keep evolving and needs regular improvement and readiness.	 the value chain. The Company has a code of conduct for board members, senior management, employees, suppliers, vendors and contractors which aligns with their commitments of ethical and transparent business practices. The Company ensures regulatory compliance across its operations/markets through proactive interaction with regulatory organisations, to reduce the risk of non-compliance. 	all the stakeholders. Negative: The Company's reputation and business continuity may be negatively impacted in the long-run due to non-compliance with
3	Cyber Security and Data Privacy	Risk	The cyber-attacks are increasing in the current environment and such attacks may directly impact the Company's operations and business. It is equally important to protect and maintain all the data of the Company.	several measures to protect its data from any internal or external threats. The IT security systems are regularly evaluated and updated to ensure continuous effectiveness thereof.	technology, digitalisation, and data integrity principles ingrained in processes ensures compliance with data security and privacy laws, protects against data loss, and facilitates productivity improvement, ultimately leading to sustainable growth in the long term. Negative: Absence of
4	R&D and Innovation Management	Opportunity	innovative products using cutting edge technologies and investments is	The Company has in-house R&D centers equipped with state-of-the art infrastructure for undertaking research and development activities from preclinical to clinical development of its products.	Positive: Creation of a robust portfolio of innovative products helps staying ahead of the competition, expanding the
5	Human Capital Development	Opportunity	Pharmaceutical industry is knowledge-based industry and is highly dependent on specialized manpower. Ability to attract and retain skilled, trained and experienced human resources has become critical due to evolution of knowledge-based economy.	 initiatives to attract and retain talent through development programs, competitive remuneration, inclusive work culture and other employee benefits programs. Employee skill enhancement through continuous training and development within and outside the Company. 	Positive: A well trained, skilled and motivated manpower help in increased productivity which is crucial for future sustainable
6	Environmental Impact Management	Risk	Non-availability of water in adequate quantity and requisite quality may impact the production and operations of the Company. It is critical to reduce the water usage through	identifies opportunities to manage its environmental impact. The Company is working on further improvements for water conservation and waste management.	legal/regulatory actions leading to financial consequences, loss of reputation and stakeholders'

S. No.	Material issue identified	Whether risk or opportunity (R/O)	Rationale for identifying the risk / opportunity	In case of risk, approach to adapt or mitigate	Financial implications of the risk or opportunity (Indicate positive or negative implications)
			optimum utilization and recycling process to create a positive environmental footprint. Focused efforts for reduced waste generation and proper disposal thereof are also important to protect the environment.	prevents leaks, and embrace technologies with lower water intensities. The Company ensures that the hazardous waste generated by its operations is safely handled and the safely handled and the safely handled are safely handled.	es er e es d
7.	Climate Change	Risk	It is critical to manage the emissions of green house gases (GHG) to protect the climate.	several measures to reduce the carbon footprint. These measure include using of grounded briquette as fuel for the boiled instead of furnace oil. It is also shifting towards using piped naturn gas (PNG) as fuel for boilers. The Company is undertaking detailed exercise to develop long-term strategic plan to reduce the carbon football.	a Positive: Adoption of climate
8.	Promoting Diversity, Equity and Inclusivity	Opportunity	Diversity, inclusivity and providing equal opportunities improves the Company's performance by bringing together people with varied knowledge, views and perspectives.		Positive: A diverse and inclusive workforce from different genders, age and special abilities brings a sense of togetherness and enables a productive environment.
9.	Occupational Health and Safety	Risk	It is important to maintain the occupational health and safety in the organization. Lack of proper Health and Safety management programs may lead to health and safety incidents.	Environment Health and Safe (EHS) management system the includes regular internal are external audits of its EHS practices. Adoption of a detailed corrective action plan post the identification of hazards and assessment of safe	y and safety incidents will have at a negative influence on the d Company's performance in terms of both safety and
10	Ethical Conduct of Clinical Trials and Animal Testing	Risk	Clinical Trials are integral part of product development in the pharmaceutical industry. There is a need to address risks associated with clinical trials and animal testing especially around the ethical and safety related concerns of trials on human subjects and animal testing. Adverse events reported during the animal testing or clinical trial can delay product development leading to increase in cost and loss of gaining business opportunity	relevant regulatory requiremen governing clinical trials and anim testing. The Company has dedicated in house teams responsible for ensuring adherence to these regulations, which involve obtaining necessary approvation permits, and maintaining thorough documentation. The Company also undertakes por marketing surveillance studies monitor the impact of new produlaunches. Long-term safety studies a also undertaken for some of the innovative products in order to assess and measure safety parameters over a longer time.	ts good clinical practices while conducting animal testing or clinical trials can have impact gon the efficacy and safety hof the products. It can also attract adverse regulatory / hegal action, lead to financial damages and reputation loss and have a negative impact on participant's health and safety. Delays at any stage can also prolong the overall timeline for drug development, leading to increased costs.



S. No.	Material issue identified	Whether risk or opportunity (R/O)	Rationale for identifying the risk / opportunity	In case of risk, approach to adapt or mitigate	Financial implications of the risk or opportunity (Indicate positive or negative implications)
			besides creating negative public perception.	 The Company also engages clinical research organizations (CROs) with proven track record and experience in conducting the clinical trials on humans wherever considered necessary. The Company has taken adequate insurance policy covering the risks associated with clinical trials to safeguard its interest against any potential loss. 	
11	Community Engagement and Development	Opportunity	community helps the Company to build	for community engagement and	engagement and development helps in building good
12	Supply Chain Management	Risk	There are some materials for which the Company is dependent on single source of supply. Such suppliers can disrupt supplies and dictate their terms. The Company also imports some of the critical materials from	The Company has entered into long-term supply agreements for key material having single source suppliers. The Company also maintains adequate inventories to take care of any temporary non-availability of imported materials. The Company is also proactively working towards expanding its supplier base, adding alternative suppliers, in order to minimize any risk associated with supply chain interruptions.	Negative: Supply chain related risks can disrupt production activities, delay in supply of products to customers, loss of business contract, attraction of penalty to supply the products on time. All these can adversely impact the Company's profitability and reputation as a

SECTION B: MANAGEMENT AND PROCESS DISCLOSURES

This section is aimed at helping businesses demonstrate the structures, policies & processes put in place towards adopting the National Guidelines on Responsible Business Conduct ("NGRBC") Principles and Core Elements.

National Guidelines on Responsible Business Conduct (NGRBC) as prescribed by the Ministry of Corporate Affairs advocates nine principles referred as P1-P9 as given below:

Principle 1 (P1) Businesses should conduct and govern themselves with integrity in a manner that is ethical, transparent and accountable.

Principle 2 (P2) Businesses should provide goods and services in a manner that is sustainable and safe.

Principle 3 (P3) Businesses should respect and promote the well-being of all employees, including those in their value chains.

Principle 4 (P4) Businesses should respect the interests of and be responsive towards all its stakeholders.

Principle 5 (P5) Businesses should respect and promote human rights.

Principle 6 (P6) Businesses should respect, protect and make efforts to restore the environment.

Principle 7 (P7) Businesses when engaging in influencing public and regulatory policy, should do so in a manner that is responsible and transparent.

Principle 8 (P8) Businesses should promote inclusive growth and equitable development.

Principle 9 (P9) Businesses should engage with and provide value to their consumers in a responsible manner.

Disc	losure	Questions	P1	P2	P3	P4	P5	P6	P7	P8	P9	
Poli	cy and	management processes			-							
1	a.	Whether your entity's policy / policies cover each principle and its core elements of the NGRBCs. (Yes/No)					Yes					
	b.	Has the policy been approved by the Board? (Yes/No)	All the policies have been formulated in consultation with the relevant stakeholders of the Company. Some of the policies have been approved by the Board as per relevant statutor requirements.									
	c.	Web Link of the Policies, if available	Relevant policies and code of conduct are available on the Company's website and can be viewed at: https://www.panaceabiotec.com/en/section/information-repository/policy									
2.		ether the entity has translated the policy into cedures. (Yes / No)	Yes, where	ever applica	ble the pr	ocedures	have bee	n defined.				
3.		the enlisted policies extend to your value in partners? (Yes/No)		Company's and the value				J ,				
4.	/ ce Stev Allia OHS	ne of the national and international codes ertifications / labels / standards (e.g. Forest wardship Council, Fairtrade, Rainforest ance, Trusted) standards (e.g. SA 8000, SAS, ISO, BIS) adopted by your entity and oped to each principle.	UnitedUnitedEnviroHealthEnergy	ial Guidelin I Nations GI I Nations Gi nment Mar I and Safety I Managem Manufactur	obal Compuiding Prin agement – ISO 450 ent Systen	pact (UN) ciples or System – 01: 2018, n ISO 500	GC) Business ISO 1400 001: 201,	and Huma 1: 2015,	ın Rights (U		g facilities	
5.	•	cific commitments, goals and targets set by entity with defined timelines, if any.	The Compachieved	oany is worl oy 2030.	king with	various s	takeholde	ers for setti	ng up goal	s and targ	ets to be	
6.	con	formance of the entity against the specific nmitments, goals and targets along-with sons in case the same are not met.	Not applic	able								

Statement by director responsible for the business responsibility report, highlighting ESG related challenges, targets and achievements

The Company aims to become one of the leading biotechnology Company. We recognize the importance of conducting business in a responsible and sustainable manner. We are implementing sustainability practices, accountability and transparency across our operations and value chain. As part of our efforts to integrate sustainability in our business we are developing a robust ESG framework, which is being built on the principles of operating responsibly and growing sustainably.

Environmental Responsibility: To achieve our target of sustainable operations, we have implemented multiple initiatives like conducting detailed assessment of all our operations to identify emissions hotspots and develop decarbonization roadways to guide individual sites to bring down their carbon emissions over medium and long term. We also conducted water use assessments across all manufacturing facilities and potential to minimize freshwater usage were identified. We plan on conducting similar audits in the future to further reduce our fresh-water consumption. We have started the review of waste management practices at our facilities to achieve our goal of minimizing waste. The Company has also undertaken multiple training programs focused on ESG to increase awareness among its

Social Responsibility: We understand that our success as a company is intricately linked to the well-being of our employees, communities and stakeholders. We have developed a culture of diversity and inclusion within our organization and currently we have more than 1,000 employees from different cultures, demographics, gender and expertise. We provide our employees a safe, healthy and competitive environment to pursue innovation in their

Governance and Ethical Practices: The Company follows the highest standard of corporate governance and ethical practices. The Company has a strong governance system to ensure regulatory compliance and internal compliances. The corporate governance system has a detailed set of practices, processes and regulations to meet the interests of all our stakeholders. The Company has a Board of Directors ('Board') that have leaders having a broad spectrum in terms of perspective, experience, expertise, gender, and culture, enriching our Company. Our Board members have rich experience of corporate functions and guide our efforts to achieve our business and sustainability goals. The Board has a subcommittee viz. Risk Management Committee to identify the potential risks, suggest ways and strategies to mitigate these risks.



As part of long-term strategy, the Company also aims to implement robust ESG program in detailed and in a quantifiable manner to evaluate the impact on the environment, society, and governance practices arising from its day-to-day business activities by prioritizing ESG issues, developing an ESG Strategy, integrating ESG strategy with business strategy, developing a robust ESG governance process and evaluation of ESG performance and monitoring.

- Details of the highest authority responsible for implementation and oversight of the Business Responsibility policy(ies).
- The business responsibility policies of the Company are broadly managed by the Board of Directors, Managing Director and the concerned departmental head(s).
- Does the entity have a specified Committee of the Board / Director responsible for decision making on sustainability related issues? (Yes / No). If yes, provide details.

The Company has a Risk Management Committee of the Board of Directors which is also responsible to oversee all aspects of sustainability and ESG.

10. Details of Review of NGRBCs by the Company:

,	Indicate whether review was undertaken by Director / Committee of the Board / Any other Committee						Frequency (Annually / Half yearly/ Quarterly/ Any other)							Any				
_	P1	P2	Р3	P4	P5	Р6	P7	P8	Р9	P1	P2	Р3	P4	P5	P6	P7	P8	P9
Performance against above policies and follow up action Compliance with statutory requirements of relevance to the principles, and rectification of any non-compliances		Committee of the Board or authorized team Periodically / Need based members																
	Committee of the Board or authorized team members						Ongoing basis											
Has the entity carried out independent	asse	ssmer	nt/	P1	P	2	P:	3	P4	l .	P5		P6	P7		P8	P9	
evaluation of the working of its policies agency? (Yes/No). If yes, provide name of	•	NO THE COMPANY GOES HOL CONGLET AN INGEDENGENT ASSESSMENT HIS									_							
- , , ,	answer to Question (1) above is "No" i.e. not a nciples are covered by a policy, reasons to be stated										NA							

SECTION C: PRINCIPLE WISE PERFORMANCE DISCLOSURE

This section is aimed at helping entities demonstrate their performance in integrating the Principles and Core Elements with key processes and decisions. The information sought is categorized as "Essential" and "Leadership". While the essential indicators are expected to be disclosed by every entity that is mandated to file this report, the leadership indicators may be voluntarily disclosed by entities which aspire to progress to a higher level in their quest to be socially, environmentally and ethically responsible.

Principle 1: Businesses should conduct and govern themselves with integrity, and in a manner that is Ethical, Transparent and Accountable.

Essential Indicators:

1. Percentage coverage by training and awareness programmes on any of the Principles during the financial year:

Segment	Total number of training and awareness programmes held	Topics / principles covered under the training and its impact	%age of persons in respective category covered by the awareness programmes
Board of Directors Key Managerial Personnel	4	The Company conducts awareness programmes for its Board of Directors at regular intervals which covers topics such as ESG parameters and targets, corporate governance practices, various other industry, business and regulatory updates	100%
Employees other than BoD and KMPs Workers	87	The employees / workers undergo various trainings / awareness sessions such as induction training at the time of joining and leadership, policy, technical and compliance training during the course of employment	100%

 Details of fines / penalties / punishment / award / compounding fees / settlement amount paid in proceedings (by the entity or by directors / KMPs) with regulators/ law enforcement agencies/ judicial institutions, in the financial year, in the following format (Note: the entity shall make disclosures on the basis of materiality as specified in Regulation 30 of SEBI LODR Regulations, 2015 and as disclosed on the entity's website):

The Company has not paid any fines or penalties in the reporting FY 2022-23 to regulatory / enforcement agencies / judicial institutions as specified in Regulation 30 of SEBI LODR Regulations, 2015.

Monetary

Monetary					
	NGRBC Principle	Name of the regulatory / enforcement agencies / judicial institutions	Amount (In INR)	Brief of the Case	Has an appeal been preferred? (Yes/No)
Penalty / Fine	NA	NA	Nil	NA	NA
Settlement	NA	NA	Nil	NA	NA
Compounding fee	NA	NA	Nil	NA	NA
Non - Monetary					
	NGRBC Principle	Name of the regulatory / enforcement agencies / judicial institutions	Brief	of the Case	Has an appeal been preferred? (Yes/No)
Imprisonment	NA	NA		NA	NA
Punishment	NA	NA		NA	NA

3. Of the instances disclosed in Question 2 above, details of the Appeal / Revision preferred in cases where monetary or non-monetary action has been appealed.

Case Details	Name of the regulatory / enforcement agencies / judicial institutions
NA	NA

4. Does the entity have an anti-corruption or anti-bribery policy? If yes, provide details in brief and if available, provide a web-link to the policy?

Yes, the Company has an anti-corruption policy. The Company is committed to conduct all aspects of its business in keeping with the highest legal and ethical standards and expects all its employees and other persons acting on its behalf to uphold this commitment. Accordingly, the Company has adopted a Zero-Tolerance approach to bribery and corruption. In accordance with this commitment, the Company has adopted Anti-Corruption Policy ('Policy') which clearly specifies this intent of the Company and is applicable to all the directors, officers, employees, agents, representatives and other associated persons of the Company (collectively "Company Personnel").

Under this Policy, the adherence to this Policy, prevention, detection and reporting of any act of Bribery or Corruption is the responsibility of all the employees of the Company. All the employees are required to avoid any activity that might lead to or suggest a breach of this Policy. In terms of the Policy, any gift or entertainment which is not proportionate and reasonable and which is not consistent with the normal business practice of developing and maintaining business relationship should not be accepted or offered. The Anti-Corruption Policy is available on website of the Company under the link, https://media.panaceabiotec.com/policy/2019/Anti_Corruption_Policy.pdf.

5. Number of Directors / KMPs / employees / workers against whom disciplinary action was taken by any law enforcement agency for the charges of bribery / corruption:

	FY 2022-23	FY 2021-22
Directors	Nil	Nil
KMPs	Nil	Nil
Employees	Nil	Nil
Workers	Nil	Nil

6. Details of complaints with regard to conflict of interest:

		Y 2022	-23	FY 20	21-22
	Number		Remarks	Number	Remarks
Number of complaints received in relation to issues of Conflict of Interest of the Directors	Nil		NA	Nil	NA
Number of complaints received in relation to issues of Conflict of Interest of the KMPs	Nil		NA	Nil	NA

7. Details of any corrective action taken or underway on issues related to fines / penalties / action taken by regulators / law enforcement agencies / judicial institutions, on cases of corruption and conflicts of interest.

None.

Leadership Indicators:

Does the entity have processes in place to avoid / manage conflict of interests involving members of the Board? (Yes/No). If Yes, provide details
of the same.

Yes, the Company's Code of Conduct requires all of its personnel including Board members to avoid and to disclose actual and apparent conflicts of personal interest with the interest of the Company and to disclose all contractual interest, whether directly or indirectly, with the Company. The Board members give disclosure of interest in other persons / entities annually as well as whenever there is a change and the same is placed before the Board for its information. The Audit Committee of the Board of Directors evaluates and approves all related party transactions as per the requirements of the Policy on Related Party Transactions as approved by the Board. All contracts / arrangements/ transactions entered by the



Company during the year under review with the related parties were approved by the Audit Committee and were undertaken in the ordinary course of business and on an arm's length basis.

Principle 2: Businesses should provide goods and services in a manner that is sustainable and safe

Essential Indicators:

 Percentage of R&D and capital expenditure (capex) investments in specific technologies to improve the environmental and social impacts of product and processes to total R&D and capex investments made by the entity, respectively.

	Current Financial Year	Previous Financial Year	Details of improvements in environmental and social impacts
R&D	100%	100%	The R&D expenditure incurred on various technologies is focused on improving the environmental or social impacts of the Company's products / processes.
Capex*	13.56%	Nil	The capital expenditure includes expenses incurred on briquette fired boiler at Lalru and purchase of electric vehicles.

^{*}Including capital work in progress.

2. a. Does the entity have procedures in place for sustainable sourcing? (Yes/No): Yes.

end of life for plastics, e-waste, hazardous and other wastes, as it is not applicable.

- b. If yes, what percentage of inputs were sourced sustainably?The Company majorly sources its input materials from the suppliers abiding by Company's Code of Conduct as applicable to them. We are
- in the process of upgrading our internal systems to capture this data point and will be disclosing the percentage in the subsequent years.

 3. Describe the processes in place to safely reclaim your products for reusing, recycling and disposing at the end of life, for (a) Plastics (including
 - packaging), (b) E-waste, (c) Hazardous waste and (d) Other waste

 Due to the nature of the Company's business, the Company does not reclaim any products for reusing, recycling and dispose these items at the
- 4. Whether Extended Producer Responsibility (EPR) is applicable to the entity's activities? (Yes / No). If yes, whether the waste collection plan is in line with the Extended Producer Responsibility (EPR) plan submitted to Pollution Control Boards? If not, provide steps taken to address the same.

Yes, the Company has an established system for collecting back the plastic waste or multi-layered packaging generated due to its products as per the EPR regulations. The recycling and disposal of the reclaimed plastics (including packaging) is carried out as per the Government rules and the provisions of the Plastic Waste Management Rules. We have engaged a waste management agency to collect and recycle plastic waste in accordance with regulatory norms.

Principle 3: Businesses should respect and promote the well-being of all employees, including those in their value chains

Essential Indicators:

1. a. Details of measures for the well-being of employees:

Category		% of employees covered by											
	Total (A)	Health in:	surance	Accident insurance		Maternity benefits		Paternity	benefits	Day Care facilities			
		Number	%	Number	%	Number	%	Number	%	Number	%		
		(B)	(B / A)	(C)	(C / A)	(D)	(D / A)	(E)	(E / A)	(F)	(F / A)		
Permanent emp	oloyees												
Male	555	555	100%	555	100%	NA	NA	0	0%	0	0%		
Female	81	81	100%	81	100%	81	100%	NA	NA	81	100%		
Total	636	636	100%	636	100%	81	13%	0	0%	81	13%		
Other than Peri	manent em	oloyees											
Male	0	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA		
Female	0	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA		
Total	0	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA		

b. Details of measures for the well-being of workers:

Category	% of workers covered by													
	Total (A)	Health in:	surance	Accident i	nsurance	Maternity	benefits	Paternity	benefits	Day Care facilities				
		Number	%	Number	%	Number	%	Number	% (E / A)	Number	%			
		(B)	(B / A)	(C)	(C / A)	(D)	(D / A)	(E)		(F)	(F / A)			
Permanent wo	rkers			• •										
Male	457	457	100%	457	100%	NA	NA	0	0%	0	0%			
Female	0	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA			
Total	457	457	100%	457	100%	-	-	0	0	0	0			
Other than Per	rmanent wor	kers		0										
Male	197	0	0%	0	0%	NA	NA	0	0%	0	0%			
Female	5	0	0%	0	0%	5	100%	NA	NA	5	100%			
Total	202	0	0%	0	0%	5	2%	0	0%	5	2%			

2. Details of retirement benefits:

		FY 2022-23			FY 2021-22	
Benefits	No. of employees covered as a % of total employees	No. of workers covered as a % of total workers	Deducted and deposited with the authority (Y/N/N.A.)	No. of employees covered as a % of total employees	No. of workers covered as a % of total workers	Deducted and deposited with the authority (Y/N/N.A.)
PF	100%	100%	Υ	100%	100%	Υ
Gratuity	100%	100%	Υ	100%	100%	Υ
ESI	12%	70%	Υ	14%	72%	Υ

3. Accessibility of workplaces:

Are the premises / offices of the entity accessible to differently abled employees and workers, as per the requirements of the Rights of Persons with Disabilities Act, 2016? If not, whether any steps are being taken by the entity in this regard.

Yes, the premises / offices of the Company are accessible to differently abled employees and workers, as per the requirements of the Rights of Persons with Disabilities Act, 2016.

- 4. Does the entity have an equal opportunity policy as per the Rights of Persons with Disabilities Act, 2016? If so, provide a web-link to the policy. Yes, the Company follows the policy of equal opportunity employer as per the Rights of Persons with Disabilities Act, 2016.
- 5. Return to work and Retention rates of permanent employees and workers that took parental leave.

Gender	Permanent e	mployees	Permanent workers		
	Return to work rate	Retention rate	Return to work rate	Retention rate	
Male	NA	NA	NA	NA	
Female	NA	NA	NA	NA	
Total	NA	NA	NA	NA	

Is there a mechanism available to receive and redress grievances for the following categories of employees and workers? If yes, give details of the mechanism in brief.

	Yes/No (If Yes, then give details of the mechanism in brief)			
Permanent Workers	The Company provides a grievance redressal procedure as part of its Whistle Blower Policy and			
Other than Permanent Workers	encourages all its employees and workers to report any instances of unethical behaviour, incidents, fraud, or violations. The Company has adopted a policy on prevention, prohibition and redressal			
Permanent Employees	of sexual harassment at workplace in line with the provisions of the Sexual Harassment of Women			
Other than Permanent Employees	at Workplace (Prevention, Prohibition and Redressal) Act, 2013 and the Rules made thereunder. Employees / workers can file any complaints / grievances related to sexual harassment under this mechanism.			

7. Membership of employees and workers in association(s) or Unions recognised by the listed entity:

Category		FY 2022-23			FY 2021-22	
	Total employees/ workers in respective category (A)	No. of employees / workers in respective category, who are part of association(s) or Union (B)	% (B / A)	Total employees/ workers in respective category (C)	No. of employees/ workers in respective category, who are part of association(s) or Union (D)	% (D / C)
Total Permanent Employee						
Male	555	0	0%	570	0	0%
Female	81	0	0%	82	0	0%
Total Permanent Workers						000
Male	457	0	0%	406	0	0%
Female	0	NA	NA	0	NA	NA

This space has intentionally been left blank.



8. Details of training given to employees and workers:

Category		FY 2022-23					FY 2021-22				
	Total (A)	On Health and Safety measures		On Skill u	On Skill upgradation		On Health and safety measures		On Skill upgradation		
	,	No. (B)	% (B/A)	No. (C)	% (C/A)		No. (E)	% (E/D)	No. (F)	% (F/D)	
Employees											
Male	555	311	56%	262	47%	570	348	61%	299	52%	
Female	81	36	44%	29	36%	82	39	48%	32	39%	
Total	636	347	55%	291	46%	652	387	59%	331	51%	
Workers											
Male	654	267	41%	0	0%	574	217	38%	0	0%	
Female	5	4	80%	0	0%	12	3	21%	0	0%	
Total	659	271	41%	0	0%	586	220	38%	0	0%	

9. Details of performance and career development reviews of employees and workers:

Category		FY 2022-23			FY 2021-22			
	Total (A)	No. (B)	% (B / A)	Total (C)	No. (D)	% (D / C)		
Employees								
Male	555	0	0%	570	0	0%		
Female	81	0	0%	82	0	0%		
Total	636	0	0%	652	0	0%		
Workers								
Male	654	0	0%	574	0	0%		
Female	5	0	0%	12	0	0%		
Total	659	0	0%	586	0	0%		

- 10. Health and safety management system:
 - a. Whether an occupational health and safety management system has been implemented by the entity? (Yes/ No). If yes, the coverage of such system?
 - Yes, the Company has occupational health and safety management system in place. The system covers all its employees, contract workers and others working with the Company.
 - b. What are the processes used to identify work-related hazards and assess risks on a routine and non-routine basis by the entity?
 - The Company undertakes periodic reviews to monitor compliance and identify and assess work-related hazards in a timely manner. The Company also provides Environment Health and Safety (EHS) training to all its personnel. The Company's process safety management system supports the implementation of best safety practices. Identification of potential risks are also undertaken through designed checklists, Hazard and Operability Studies (HAZOP), Hazard Identification and Risk Assessment (HIRA) and other consequence modelling studies.
 - c. Whether you have processes for workers to report the work related hazards and to remove themselves from such risks. (Y/N) Yes.
 - d. Do the employees / worker of the entity have access to non-occupational medical and healthcare services? (Yes/ No)
 - Yes, the Company provides its employees and workers with non-occupational medical and healthcare services. Moreover, the Company ensures that all of its employees and workers have access to medical insurance.
- 11. Details of safety related incidents:

Safety Incident / Number	Category	FY 2022-23	FY 2021-22
Lost Time Injury Frequency Rate (LTIFR) (per one	Employees	Nil	Nil
million-person hours worked)	Workers	Nil	Nil
Total recordable work-related injuries	Employees	Nil	Nil
	Workers	Nil	Nil
No. of fatalities	Employees	Nil	Nil
	Workers	Nil	Nil
High consequence work-related injury or ill-health	Employees	Nil	Nil
(excluding fatalities)	Workers	Nil	Nil

12. Describe the measures taken by the entity to ensure a safe and healthy work place.

The Company encourages and ensures safe working environment with reduced accidents and incidents trends. The employees and workers are made aware about the safety trainings and procedures as soon as they join the Company. It also conducts regular sessions and mock drills to update them with the system. The Company also ensures that the deployed contractor's workers are having mandatory PPEs and trained in safety & respective job work training before starting their job work.

13. Number of Complaints on the following made by employees and workers:

		FY 2022-23			FY 2021-22		
	Filed during the year	Pending resolution at the end of year	Remarks	Filed during the year	Pending resolution at the end of year	Remarks	
Working conditions	Nil	Nil	NA	Nil	Nil	NA	
Health & Safety	Nil	Nil	NA	Nil	Nil	NA	

14. Assessments for the year:

	% of your plants and offices that were assessed (by entity or statutory authorities or third parties)
Health and safety practices	100%
Working Conditions	100%

15. Provide details of any corrective action taken or underway to address safety-related incidents (if any) and on significant risks / concerns arising from assessments of health & safety practices and working conditions.

In case any case is reported, the observations of audit are recorded, corrective actions planned and tracked. The feedback is provided to the auditing agency for their agreement.

Leadership Indicators:

1. Does the entity extend any life insurance or any compensatory package in the event of death of:

(A) Employees (Y / N) : Yes(B) Workers (Y / N) : Yes

2. Provide the measures undertaken by the entity to ensure that statutory dues have been deducted and deposited by the value chain partners.

The Company obtains necessary proofs from the value chain partners in respect of the statutory dues deducted and deposited by them.

3. Provide the number of employees / workers having suffered high consequence work related injury / ill-health / fatalities (as reported in Q11 of Essential Indicators above), who have been rehabilitated and placed in suitable employment or whose family members have been placed in suitable employment:

	Total no. of affected employees / workers			No. of employees / workers that are rehabilitated and placed in suitable employment or whose family members have been placed in suitable employment			
	FY 2022-23	FY 2021-22		FY 2022-23	FY 2021-22		
Employees	Nil	Nil		Nil	Nil		
Workers	Nil	Nil		Nil	Nil		

Principle 4: Businesses should respect the interests of and be responsive to all its stakeholders

Essential Indicators:

1. Describe the processes for identifying key stakeholder groups of the entity.

The Company regularly engages with a number of stakeholders including employees, shareholders, customers, suppliers, government agencies, industry associations, not for profit organizations and communities. The Company identifies key stakeholders group on the basis of industry dynamic, business model and the influence and impact they have on the Company.

2. List stakeholder groups identified as key for your entity and the frequency of engagement with each stakeholder group.

Stakeholder Group	Whether identified as Vulnerable & Marginalized Group (Yes/No)	Channels of communication (E-mail, SMS, Newspaper, Pamphlets, Advertisement, Community Meetings, Notice Board, Website, Other)	Frequency of engagement (Annually / Half yearly / Quarterly/ others)	Purpose and scope of engagement including key topics and concerns raised during such engagement
Employees	No	Leadership development training, Performance Evaluation, Continuous Feedback, Employee induction, Emails communications.	Periodical / need based	Training and development of employees, health and safety, career growth and quality of work & life.



Stakeholder Group	Whether identified as Vulnerable & Marginalized Group (Yes/No)	Channels of communication (E-mail, SMS, Newspaper, Pamphlets, Advertisement, Community Meetings, Notice Board, Website, Other)	Frequency of engagement (Annually / Half yearly / Quarterly/ others)	Purpose and scope of engagement including key topics and concerns raised during such engagement
Shareholders	No	Annual Reports, Quarterly Results, Company Website and intimation to Stock exchanges	Quarterly / annual / need based	Transparency, Good Governance, building reputation and brand image
Customers	No	Virtual meetings / email communications / visits	Need based	Market opportunities, business growth, end customer feedback, business forecast
Suppliers	No	Virtual meetings / email communications / visits	Need based	Supply chain matter, quality compliance, forecast and delivery of products
Government agencies	No	Applicable reports, intimations, virtual / physical meetings	Periodical / need based	Ensuring timely compliance with applicable laws, industry matters
Local communities	No	Interaction with community members	Need based	Addressing any specific issues, creating awareness, local employment generation

Principle 5: Businesses should respect and promote human rights

Essential Indicators:

1. Employees and workers who have been provided training on human rights issues and policy(ies) of the entity:

Category		FY 2022-23		FY 2021-22			
	Total (A)	No. of employees / workers covered (B)	% (B/A)	Total (C)	No. of employees / workers covered (D)	% (D/C)	
Employees							
Permanent	636	331	52%	652	280	43%	
Other than permanent	0	0	NA	0	0	NA	
Total Employees	636	331	52%	652	280	43%	
Workers							
Permanent	457	224	49%	406	158	39%	
Other than permanent	202	81	40%	180	67	37%	
Total Employees	659	305	46%	586	225	38%	

2. Details of minimum wages paid to employees and workers:

Category	FY 2022-23					FY 2021-22				
	Total (A) Equal to M Wag					Minimum age		More than Minimum Wage		
• • •		No. (B)	% (B/A)	No.(C)	% (C/A)		No.(E)	% (E/D)	No.(F)	% (F/D)
Employees										
Permanent										
Male	555	14	3%	541	97%	570	22	4%	548	96%
Female	81	0	0%	81	100%	82	7	9%	75	91%
Other than permanent										
Male	0	NA	NA	NA	NA	0	NA	NA	NA	NA
Female	0	NA	NA	NA	NA	0	NA	NA	NA	NA
Workers			•	0						
Permanent										
Male	457	25	5%	432	95%	406	33	8%	373	92%
Female	0	NA	NA	NA	NA	0	NA	NA	NA	NA
Other than permanent			•							
Male	197	197	100%			168	168	100%	-	-
Female	5	5	100%		-	12	12	100%	-	-

3. Details of remuneration/salary/wages:

(₹ in million)

		Male	Female		
	Number	Median remuneration / salary / wages of respective category	Number	Median remuneration / salary / wages of respective category	
Board of Directors (BoD)*	3	7.56	0	NA	
Key Managerial Personnel (KMP)#	2	6.19	0	NA	
Employees other than BoD and KMP	550	0.51	81	0.51	
Workers	457	0.16	0	NA	

^{*} Executive Directors only

4. Do you have a focal point (Individual / Committee) responsible for addressing human rights impacts or issues caused or contributed to by the business? (Yes/No)

Yes, the Company's Human Resources Department is responsible for monitoring and addressing human rights impacts and issues. As part of its human resource policy, the Company expects all its key stakeholders to respect and comply with the policy principles, as well as all applicable laws and regulations, across the organization.

5. Describe the internal mechanisms in place to redress grievances related to human rights issues.

The human rights related issues can be addressed through the open channels of communication and through the mechanism prescribed under the Company's Whistle Blower Policy.

6. Number of Complaints on the following made by employees and workers:

Category	FY 2022-23			FY 2021-22		
	Filed during the year	Pending resolution at the end of year	Remarks	Filed during the year	Pending resolution at the end of year	Remarks
Sexual Harassment	-	-		-	-	
Discrimination at workplace	-	-		-	-	
Child Labour	-	-		-	- ,	
Forced Labour / Involuntary Labour	-	-		-		
Wages	-	-		-	· -	
Other human rights related issues	-	-		-	·	

7. Mechanisms to prevent adverse consequences to the complainant in discrimination and harassment cases.

The Company is committed to and follows the highest standards of ethical, moral and legal conduct of business operations. To maintain these standards, the Company encourages its employees who have concerns about suspected misconduct to come forward and express these concerns without fear of punishment or unfair treatment. The Whistle Blower Policy and the Prevention of Sexual Harassment (POSH) ensures the protection of the concerned individual(s) and safeguard them at work against any retaliation or reprisal. The Company proceeds with the corrective measures after assuring the confidence in the complaint raised is genuine and not made in the spirit of damaging someone's reputation, which prevents adverse consequences of false allegations.

8. Do human rights requirements form part of your business agreements and contracts?(Yes/No) Yes

9. Assessments for the year:

	% of your plants and offices that were assessed (by entity or statutory authorities or third parties)
Child labour	100%
Forced / involuntary labour	100%
Sexual harassment	100%
Discrimination at workplace	100%
Wages	100%

All the locations under the entity are assessed by the entity on the above parameters, complying with the requirements of the Shops and Establishments Act for offices, and the Factories Act at plants and R&D centres.

10. Provide details of any corrective actions taken or underway to address significant risks / concerns arising from the assessments at Question 9

No significant risks / concerns were noted during the assessments as mentioned above.

[#] Other than Executive Directors



Principle 6: Businesses should respect and make efforts to protect and restore the environment

Essential Indicators:

1. Details of total energy consumption (in Joules or multiples) and energy intensity:

Parameter	FY 2022-23	FY 2021-22
Total electricity consumption (units in Gigajoules (GJ)) (A)	79,185.92	75,031.38
Total fuel consumption (units in GJ) (B)	64,116.03	89,566.18
Energy consumption through other sources (units in GJ) (C)	28,043.74	9,573.03
Total energy consumption (GJ) (A+B+C)	171,345.69	174,170.59
Energy intensity per rupee of turnover (Total energy consumption / turnover in million rupees)	66.94	74.10

Does the entity have any sites / facilities identified as designated consumers (DCs) under the Performance, Achieve and Trade (PAT) Scheme of
the Government of India? (Y/N) If yes, disclose whether targets set under the PAT scheme have been achieved. In case targets have not been
achieved, provide the remedial action taken, if any.

No

3. Provide details of the following disclosures related to water:

Parameter	FY 2022-23	FY 2021-22
Water withdrawal by source (in kilolitres)		
(i) Surface water	Nil	Nil
(ii) Ground water	248,569	243,480
(iii) Third party water	Nil	Nil
(iv) Seawater / desalinated water	Nil	Nil
(v) Others	Nil	Nil
Total volume of water withdrawal (in kilolitres) $(i + ii + iii + iv + v)$	248,569	243,480
Total volume of water consumption (in kilolitres)	248,569	243,480
Water intensity per rupee of turnover in million (Water consumed / turnover)	96.69	103.39

- 4. Has the entity implemented a mechanism for Zero Liquid Discharge? If yes, provide details of its coverage and implementation.

 No, the entity has not implemented a mechanism for Zero Liquid Discharge.
- 5. Details of air emissions (other than GHG emissions) by the entity:

Parameter	Unit	FY 2022-23	FY 2021-22
Nox	ug/m³	23.4	27.9
Sox	ug/m³	21.8	21.6
Particulate Matter (PM)	ug/m³	79.7	81.6
Persistent Organic Pollutants (POP)		-	-
Volatile Organic Compounds (VOC)		-	-
Hazardous Air Pollutants (HAP)		-	-
Others		<u>-</u>	-

6. Details of greenhouse gas emissions (Scope 1 and Scope 2 emissions) & its intensity:

Parameter	Unit	FY 2022-23	FY 2021-22
Total Scope 1 emissions (Break-up of the GHG into CO_2 , CH_4 , N_2O , HFCs, PFCs, SF_6 , NF_3 , if available)	Metric tonnes of CO ₂ equivalent	-	-
Total Scope 2 emissions (Break-up of the GHG into ${\rm CO_{2'}}$ ${\rm CH_{4'}N_{2}O}$, HFCs, PFCs, SF $_{6'}$, NF $_{3'}$ if available)	Metric tonnes of CO ₂ equivalent	-	-
Total Scope 1 and Scope 2 emissions per rupee of turnover		-	-

Does the entity have any project related to reducing Green House Gas emission? If Yes, then provide details.
 No, the entity does not have any project related to reducing Green House Gas emission for the FY 2022-23.

8. Details related to waste management by the entity:

(iii) Other disposal operations

Parameter	FY 2022-23	FY 2021-22
Total Waste generated (in metric tonnes)		
Plastic waste (A)	89.05	Nil
E-waste (B)	0.68	1.22
Bio-medical waste (C)	62.70	52.58
Construction and demolition waste (D)	Nil	Nil
Battery waste (E)	Returned to vendors under buyback policy	Returned to vendors under buyback policy
Radioactive waste (F)	Nil	Nil
Other Hazardous waste, if any (G):		
Drums (in nos.)	2,015	2,964
Used oil (in metric tons)	-	2.39
Other Non-hazardous waste generated (H), if any	439.11	354.98
(Break-up by composition i.e. by materials relevant to the sector)		
Total $(A+B+C+D+E+F+G+H)$	591.54 metric ton and 2015 drums	411.18 metric ton and 2964 drums
For each category of waste generated, total waste recovered through recy	cling, re-using or other recovery opera	ations (in metric tonnes)
Category of waste		

(i) Recycled	89.05 (Plastic waste)	Nil
(ii) Re-used	Nil	2.39 (Used Oil)
(iii) Other recovery operations	Nil	Nil
Total	89.05	2.39
For each category of waste generated, total waste disposed by nature of	disposal method (in metric tonnes)	
Category of waste		
(i) Incineration	62.70	52.58
(ii) Landfilling	39.12	53.42

Nil

Total 101.82 106.00

9. Briefly describe the waste management practices adopted in your establishments. Describe the strategy adopted by your company to reduce usage of hazardous and toxic chemicals in your products and processes and the practices adopted to manage such wastes.

The Company has established a matrix for product waste generations and disposal methods to ensure the zero environmental burden. The Company has all the required approvals and authorizations for recycling, landfills, incineration of the waste materials in accordance with the governmental rules and regulations.

10. If the entity has operations / offices in / around ecologically sensitive areas (such as national parks, wildlife sanctuaries, biosphere reserves, wetlands, biodiversity hotspots, forests, coastal regulation zones etc.) where environmental approvals / clearances are required, please specify details:

S. No.	Location of operations/offices	Type of operations	Whether the conditions of environmental approval / clearance are being complied with? (Y/N) If no, the reasons thereof and corrective action taken, if any.
			NA

The Company does not have any operations / offices in / around ecologically sensitive areas (such as national parks, wildlife sanctuaries, biosphere reserves, wetlands, biodiversity hotspots, forests, coastal regulation zones, etc.) where environmental approvals / clearances are required.

11. Details of environmental impact assessments of projects undertaken by the entity based on applicable laws, in the current financial year:

Name and brief details	EIA Notification No.	Date	Whether conducted by independent external agency (Yes / No)	Results communicated in public domain (Yes / No)	Relevant Web link	
No environmental impact assessment carried out during this period						

12. Is the entity compliant with the applicable environmental law / regulations / guidelines in India; such as the Water (Prevention and Control of Pollution) Act, Air (Prevention and Control of Pollution) Act, and Environment Protection Act and Rules thereunder (Y/N). If not, provide details of all such non-compliances.



S. No.	Specify the law / regulation / guidelines which was not complied with	Provide details of the non- compliance	Any fines / penalties /action taken by regulatory agencies such as pollution control boards or by courts	Corrective action taken, if any
		NA		

The Company is compliant with the applicable environmental law / regulations / guidelines in India; such as the Water (Prevention and Control of Pollution) Act, Air (Prevention and Control of Pollution) Act, and Environment Protection Act and Rules thereunder.

Leadership Indicators:

1. Break-up of the total energy consumed (in Joules or multiples) from renewable and non-renewable sources:

Parameter	FY 2022-23	FY 2021-22
From renewable sources		
Total electricity consumption (units in Gigajoules (GJ)) (A)	-	-
Total fuel consumption (GJ) (B)	-	-
Energy consumption through other sources (GJ) (C)	28,043.74	9,573.03
Total energy consumed from renewable sources (GJ) (A+B+C)	28,043.74	9,573.03
From non-renewable sources		
Total electricity consumption (D)	79,185.92	75,031.38
Total fuel consumption (E)	64,116.03	89,566.18
Energy consumption through other sources (F)	-	-
Total energy consumed from non-renewable sources (D+E+F)	143,301.95	164,597.56
Details related to water discharged:		
Parameter	FY 2022-23	FY 2021-22
Water discharge by destination and level of treatment (in kilolitres)		
(i) To Surface water	NA	NA
- No treatment		

61,615

NA

NA

NA

61,615

55,617

NA

 $\mathsf{N}\mathsf{A}$

NA

55,617

- With treatment (ii) To Groundwater

2.

No treatmentWith treatment

(iii) To SeawaterNo treatmentWith treatment(iv) Sent to third parties

No treatmentWith treatment(v) Others

No treatmentWith treatment

Total water discharged (in kilolitres)

3. Water withdrawal, consumption and discharge in areas of water stress (in kilolitres):

For each facility / plant located in areas of water stress:

- (i) Name of the area: Lalru, Baddi & Delhi
- (ii) Nature of operations:- Pharmaceutical
- (iii) Water withdrawal, consumption and discharge:

Parameter					FY 2022-23	FY 2021-22
Water withdrawal by source (in kilolitres)						
(i) Surface water					NA	NA
(ii) Groundwater					248,569	243,480
(iii) Third party water					NA	NA
(iv) Seawater / desalinated water					NA	NA
(v) Others					NA	NA
Total volume of water withdrawal (in kilolitre	es)			-	248,569	243,480

Parameter	FY 2022-23	FY 2021-22
Total volume of water consumption (in kilolitres)	248,569	243,480
Water intensity per rupee of turnover (Water consumed / turnover)	97.11	103.59
Water discharge by destination and level of treatment (in kilolitres)		
(i) Into Surface water	Nil	Nil
- No treatment		
- With treatment		
(ii) Into Groundwater	Nil	Nil
- No treatment		
- With treatment		
(iii) Into Seawater	Nil	Nil
- No treatment		
- With treatment		
(iv) Sent to third-parties	Nil	Nil
- No treatment		
- With treatment		
(v) Others	Nil	Nil
- No treatment		
- With treatment		
Total water discharged (in kilolitres)	248,569	243,480

Note: No independent assessment / evaluation / assurance has been carried out by an external agency.

4. Details of total Scope 3 emissions & its intensity:

Parameter	Unit	FY 2022-23	FY 2021-22
Total Scope 3 emissions (Break-up of the GHG into $CO_{2'}$ $CH_{4'}$ N_2O , HFCs, PFCs, SF $_{6'}$ NF $_{3'}$ if available)	Metric tonnes of CO ₂ equivalent	-	.
Total Scope 3 emissions per rupee of turnover			

5. With respect to the ecologically sensitive areas reported at Question 10 of Essential Indicators above, provide details of significant direct & indirect impact of the entity on biodiversity in such areas along-with prevention and remediation activities.

Not applicable.

6. If the entity has undertaken any specific initiatives or used innovative technology or solutions to improve resource efficiency, or reduce impact due to emissions / effluent discharge / waste generated, please provide details of the same as well as outcome of such initiatives:

S. No.	Initiative undertaken	Details of the initiative (Web-link, if any, along-with summary)	come of the	initiative	
i)	The project activity involving fuel switch from fossil fuel	The main purpose of appropriately using biomass (a renewable fuel) for steam generation:	Estimated amount of emission red over 10 years period		
	(FO) to biomass briquettes has been envisaged at Baddi	, volume and surface of (10)	Location	CO ₂ e Ton.	Remarks
& Lalru location.	 Generation of steam in an environmentally friendly manner. 	Baddi	31,140	Commissioned	
	- Reduction in greenhouse gas (GHG) i.e. ${\rm CO_2}$ emissions.	Lalru	34,370	Commissioned	
			Total	65,510	

7. Does the entity have a business continuity and disaster management plan? Give details in 100 words / web link.

Yes, the Company has developed robust business continuity and disaster management plan to restore the operation in the shortest possible term in case of any disasters with the objective of ensuring business continuity.

This business continuity plan enables the Company to adapt in situations arising from any natural calamity or an unprecedented event which may disrupt the business operations. The Company continuously enhances its existing plan by incorporating interferences and observations from disruptions faced in the unprecedented situations. Further, the Company's risk management plan enables the minimisation of disaster-linked losses, by assessing the potential major disruption with its consequent risks to the business and by providing the appropriate mitigation action plans.



The purpose of the program is to maintain a continuing state of emergency readiness and response. The plan would be invoked to manage all emergencies using all the available resources effectively in order to ensure smooth business operations and to protect life and property.

- 8. Disclose any significant adverse impact to the environment, arising from the value chain of the entity. What mitigation or adaptation measures have been taken by the entity in this regard.
 - No such significant adverse impact to the environment, arising from the value chain of the entity.
- 9. Percentage of value chain partners (by value of business done with such partners) that were assessed for environmental impacts.

 None.

Principle 7: Businesses, when engaging in influencing public and regulatory policy, should do so in a manner that is responsible and transparent

Essential Indicators:

- 1. a. Number of affiliations with trade and industry chambers / associations.
 - b. List the top 10 trade and industry chambers / associations (determined based on the total members of such body) entity is a member of/affiliated to.

S. No.	Name of the trade and industry chambers / associations	Reach of trade and industry chambers/ associations (State / National)
1	Indian Pharmaceutical Alliance	National
2	The Indian Drug Manufacturers Association	National
3	Confederation of Indian Industry	National
4	Delhi Chamber of Commerce	State
5	Federation of Indian Export Organisation (FIEO)	National
5	Pharmaceuticals Export Promotion Council of India	National
7	Developing Countries Vaccine Manufacturers Network	International

 Details of corrective action taken or underway on any issues related to anti-competitive conduct by the entity, based on adverse orders from regulatory authorities.

During FY 2022-23, there were no cases reported against the Company related to anti-competitive conduct.

Principle 8: Businesses should promote inclusive growth and equitable development

Essential Indicators:

- Details of Social Impact Assessments (SIA) of projects undertaken by the entity based on applicable laws, in the current financial year.
 The Company did not have any mandatory requirement of SIA for any of its projects.
- 2. Information on project(s) for which ongoing Rehabilitation and Resettlement (R&R), being undertaken by your entity: Not Applicable
- Describe the mechanisms to receive and redress grievances of the community.
 The Company interacts with local community members to understand their grievances, if any, and act upon them accordingly.
- 4. Percentage of input material (inputs to total inputs by value) sourced from suppliers:

	FY 2022-23	FY 2021-22
Directly sourced from MSMEs / small producers	2.27%	0.62%
Sourced directly from within the district and neighbouring districts	4.66%	2.71%

Principle 9: Businesses should engage with and provide value to their consumers in a responsible manner

Essential Indicators:

Describe the mechanisms in place to receive and respond to consumer complaints and feedback.

The Company has a comprehensive complaint management process to address any product quality complaints received by it. The Company

may receive a product quality complaint either directly or through a third-party. As soon as the complaint is received, it is registered in the Company's system, acknowledged, and a preliminary assessment is initiated. Along with the initial evaluation, a follow-up is initiated for requesting the complaint sample and any additional information to facilitate the preliminary assessment and the investigation. A remedial corrective and preventive action plan is launched after the investigation is completed and the root cause is determined. A complaint summary report is also prepared at the same time. The complaint is finally closed after a final risk assessment is completed and a response is delivered to the complainant. Any market actions for the impacted product are considered and may be communicated with the local regulatory authorities depending on local requirements. The Company has a pharmacovigilance policy and mechanism in place, which is supported by a competent team and third party consultants, committed to responding to patient safety concerns and incidents.

2. Turnover of products and / or services as a percentage of turnover from all products / service that carry information about:

	As a percentage to total turnover
Environmental and social parameters relevant to the product	-
Safe and responsible usage	100%
Recycling and/or safe disposal	-

3. Number of consumer complaints in respect of the following:

		FY 2022-23			FY 2021-22		
	Received during the year	Pending resolution at the end of year	Remarks	Received during the year	Pending resolution at the end of year	Remarks	
Data privacy	0	0	NA	0	0	NA	
Advertising	0	0	NA	0	0	NA	
Cyber-security	0	0	NA	0	0	NA	
Delivery of essential services	0	0	NA	0	0	NA	
Restrictive Trade Practices	0	0	NA	0	0	NA	
Unfair Trade Practices	0	0	NA	0	0	NA	
Other	0	0	NA	0	0	NA	

4. Details of instances of product recalls on account of safety issues:

	Number	Reasons for recall
Voluntary recalls	Nil	NA
Forced recalls	Nil	NA

5. Does the entity have a framework / policy on cyber security and risks related to data privacy? (Yes/No) If available, provide a web-link of the policy.

Yes, the Company has a robust framework in place to manage data privacy and cyber security. To ensure the cyber security it uses antivirus, antispyware protection and firewalls to protect against any possible breach. For maintaining data privacy and security, the Company uses remote data back-ups, latest versions of software through secured computers and servers to mitigate the technology risks. The framework on data privacy and cyber security is internally available to the relevant stakeholders on the intranet.

6. Provide details of any corrective actions taken or underway on issues relating to advertising, and delivery of essential services; cyber security and data privacy of customers; re-occurrence of instances of product recalls; penalty / action taken by regulatory authorities on safety of products / services.

Not applicable.

For and on behalf of the Board

Place : New Delhi Dr. Rajesh Jain
Date : August 12, 2023 Chairman and Managing Director